Always a chance. The AE37 vaccine looks more potent than E75 (Neuvax). The environment for getting financing in biotech is better now than it was a few years ago. If the cost of a partnership or buyout of Galena is too much for a big pharma like Roche they might choose to help develop AE37 instead.
First to market is key though. Galena is already well into their Phase III whereas Antigen Express has not yet submitted a protocol for their Phase III. Lot of catching up to do because Fletcher did not keep his promise about roll out nor was he able to raise significant amount of money to do the development. He only raised money for his salary.